original ) (raw )Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
Sebastián Moyano
Rheumatology and Therapy
View PDFchevron_right
Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Björn Guðbjörnsson
Arthritis Care & Research, 2021
View PDFchevron_right
PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
Rubén Queiro
Rheumatology and therapy, 2022
View PDFchevron_right
Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study
Paola Volpe
Reumatismo, 2020
View PDFchevron_right
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Martin M Schumacher
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
Elisa Camela
Dermatologic Therapy
View PDFchevron_right
Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab
D. Wilsmann-Theis
Dermatology Online Journal, 2020
View PDFchevron_right
Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis
Tali Eviatar
Clinical and Experimental Rheumatology, 2022
View PDFchevron_right
Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
Daniel Costache
Psoriasis, 2024
View PDFchevron_right
Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study
D. Wilsmann-Theis
Journal of Dermatological Treatment, 2020
View PDFchevron_right
Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
wendy cantrell
American journal of clinical dermatology, 2015
View PDFchevron_right
SAT0430 SECUKINUMAB EFFECTIVENESS IN 1543 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CLINICAL PRACTICE IN 13 EUROPEAN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
Björn Guðbjörnsson
Annals of the Rheumatic Diseases, 2020
View PDFchevron_right
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Roberta Ramonda
Research Square (Research Square), 2024
View PDFchevron_right
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
jose del giudice
Lancet (London, England), 2017
View PDFchevron_right
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study
Martina Burlando
American Journal of Clinical Dermatology, 2019
View PDFchevron_right
Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study
Rosario Foti
BMC Rheumatology
View PDFchevron_right
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Mariagrazia Lorenzin
RMD Open
View PDFchevron_right
Response toIL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of theIL‐17A gene: results from a multicentre study of four European psoriasis cohorts
Marina Talamonti
Journal of the European Academy of Dermatology and Venereology, 2019
View PDFchevron_right
Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab
Ana Ravić-nikolić
Serbian Journal of Experimental and Clinical Research
View PDFchevron_right
Data from the Romanian Registry of Rheumatic Diseases for patients with psoriatic arthritis treated with biologic disease-modifying anti-rheumatic drugs during 2019
M. Parvu
Romanian Journal of Rheumatology, 2020
View PDFchevron_right
Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis
heng yan
Immunotherapy, 2015
View PDFchevron_right
Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting
Maria Sole Chimenti
Clinical Rheumatology, 2020
View PDFchevron_right
Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study
Juergen Rech
Arthritis Research & Therapy
View PDFchevron_right
Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
Amir Haddad
Biologics : Targets & Therapy, 2021
View PDFchevron_right
OP0220 SECULAR Trends in Baseline Characteristics, Treatment Retention and Response Rates in 17453 Bionaïve Psoriatic Arthritis Patients Initiating Tnfi – Results from the Eurospa Collaboration
Bjorn Gudbjornsson
Annals of the Rheumatic Diseases, 2021
View PDFchevron_right
Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study
Roberta Ramonda
Clinical Rheumatology, 2021
View PDFchevron_right
Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece
E. Sotiriou
Journal of the European Academy of Dermatology and Venereology : JEADV, 2018
View PDFchevron_right
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Wim Noël
HAL (Le Centre pour la Communication Scientifique Directe), 2023
View PDFchevron_right
Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection
Abin P Puravath
Journal of Inflammation Research, 2021
View PDFchevron_right
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey
Enzo Berardesca
Dermatologic therapy, 2017
View PDFchevron_right
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Diamant Thaci
Journal of the European Academy of Dermatology and Venereology, 2018
View PDFchevron_right
Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison
DAMIEN LOEUILLE
Rheumatology, 2020
View PDFchevron_right